Evaluation of the effect of Omega-3 in patients with myocardial infarction

Evaluation of the effects of Omega-3 on the hs-CRP level in patients with myocardial infarction following 4 weeks after discharge

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220516054874N5

Enrollment

Registered

2022-08-17

Start date

2022-09-06

Completion date

Unknown

Last updated

2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial infarction. ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction

Interventions

Intervention 1: Intervention group: Patients with myocardial infarction receive standard treatment (ASA 80 mg, clopidogrel 75 mg and atorvastatin 80 mg) along with Omega-3 capsules prepared by Karen P

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with myocardial infarction according to the American College of Heart criteria Consent to admission to the study Age more than 18 years old

Exclusion criteria

Exclusion criteria: Pregnant women Allergy to omega-3 Kidney failure under hemodialysis Severe liver failure with liver enzymes three times more than normal Treatment with corticosteroids or immunosuppressive drugs Treatment with diltiazem or verapamil Previous treatment with Omega-3

Design outcomes

Primary

Measure	Time frame
Changes in hs-CRP serum level. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Laboratory kit using an ELISA reader.	—

Secondary

Measure	Time frame
Changes in LDL levels. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Using an autoanalyzer.;Mortality. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Using medical records of patients.;Re-hospitalization. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Using medical records of patients.;Arrhythmia. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Using medical records of patients.;Sudden cardiac death. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Using medical records of patients.;Changes in HDL levels. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Using an autoanalyzer.;Changes in cholesterol levels. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Using an autoanalyzer.;Changes in triglycerides levels. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Using an autoanalyzer.	—

Measure

Time frame

Changes in LDL levels. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Using an autoanalyzer.;Mortality. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Using medical records of patients.;Re-hospitalization. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Using medical records of patients.;Arrhythmia. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Using medical records of patients.;Sudden cardiac death. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Using medical records of patients.;Changes in HDL levels. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Using an autoanalyzer.;Changes in cholesterol levels. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Using an autoanalyzer.;Changes in triglycerides levels. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Using an autoanalyzer.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Vafa Baradaran Rahimi

Mashhad University of Medical Sciences

baradaranrv@mums.ac.ir0095 5138012739

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026